STAT+: Many Cancer Patients Don’t Get Genomic Tests to Guide Treatment, Study Finds

Why It Matters

The testing gap limits patients’ ability to benefit from effective targeted drugs and widens health inequities, ultimately increasing overall treatment costs for the healthcare system.

Key Takeaways

• Only ~50% of metastatic patients receive genomic sequencing
• Low-income, Medicare/Medicaid, Black, Hispanic patients lag behind
• Sequencing gaps limit access to targeted therapies
• Early testing improves survival, yet disparities persist
• Policy interventions needed to standardize testing

Pulse Analysis

Genomic profiling has become a cornerstone of precision oncology, allowing clinicians to match patients with drugs that target specific mutations. The recent JAMA Network Open analysis of five metastatic cancer types revealed that roughly half of eligible patients underwent tumor sequencing, a figure that falls short of clinical guidelines recommending early testing. The study also highlighted a stark socioeconomic gradient: individuals on Medicare or Medicaid, as well as Black and Hispanic patients, were significantly less likely to receive the test. These gaps suggest that many patients are missing out on therapies that could extend survival or reduce toxicity.

Beyond individual outcomes, the underutilization of genomic tests threatens the broader economics of cancer care. Targeted agents often cost more upfront than conventional chemotherapy, yet they can lower downstream expenses by avoiding ineffective treatments and hospitalizations. When a sizable portion of the population is excluded from testing, payers lose the opportunity to channel resources toward high‑value interventions, and health disparities widen. Moreover, clinical trial enrollment, which increasingly depends on molecular eligibility, may become skewed, limiting the generalizability of research findings and slowing innovation.

Addressing these inequities will require coordinated action from insurers, providers, and policymakers. Medicare could tie reimbursement to documented testing for eligible cancers, while Medicaid programs might adopt uniform coverage policies that eliminate prior‑authorization hurdles. Hospital systems should embed reflex testing protocols that automatically trigger sequencing when a metastatic diagnosis is entered. At the federal level, expanding the Cancer Moonshot’s data infrastructure to track test utilization by demographic variables could inform targeted outreach. Such measures would not only improve patient outcomes but also enhance the cost‑effectiveness of the oncology ecosystem.